2022 Comprehensive Covid-19 Guide https://www.cms.gov/files/document/COVID-19-toolkit-issuers-MA-plans.pdf
https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion
Monoclonal EUA for Protection against Covid-19 On December 8, 2021, the FDA issued an Emergency Use Authorization (EUA) for the administration of AstraZeneca’s two-drug Evusheld monoclonal antibody therapy for the prevention of COVID-19 in certain adults. The combination monoclonal antibiotic therapy consisting of tixagevimab with cilgavimab is authorized as a pre-exposure option for patients over the age of 12 who weigh at least 88 pounds and have either of the following:
The patient has moderate to severe immunocompromised systems due to medical conditions or treatments that may prevent an effective COVID-19 vaccination or; The patient exhibited an adverse reaction to previous COVID-19 vaccinations, indicating that additional vaccines following vaccine schedules are not recommended. The EUA indicates Evusheld may be administered at least two weeks following vaccination.
© 2022 PARA HealthCare Analytics, an HFRI Company – January 2022 CPT® is a registered trademark of the American Medical Association
Page 30
